Skip to main content
NCBI home page
Gut logoLink to Gut
. 1990 Nov;31(11):1242–1245. doi: 10.1136/gut.31.11.1242

Paf-acether synthesis by Helicobacter pylori.

Y Denizot 1, I Sobhani 1, J C Rambaud 1, M Lewin 1, Y Thomas 1, J Benveniste 1
PMCID: PMC1378692  PMID: 2253906

Abstract

Clinical studies suggest that Helicobacter pylori may play a role in the pathogenesis of gastroduodenal ulcers in man but direct evidence of mucosal injury by this microorganism is still lacking. Paf-acether (paf) causes a number of disorders including ischaemic bowel necrosis and gastroduodenal ulceration. Since paf is produced by Escherichia coli, we investigated whether it could be synthesised by H pylori. Five H pylori isolates were collected from antral biopsy specimens from patients with gastritis and duodenal ulcer and cultured with selective antibiotics. Colonies obtained from both blood agar and brucella broth medium were used. Paf was determined by platelet aggregation assay after ethanolic extraction and subsequent purification by high performance liquid chromatography. Paf was detected in H pylori in blood agar plates (680 (390) pg paf/1 x 10(6) organisms) but not in bacteria cultured on brucella broth medium. Supplementation of the latter medium with lyso paf and acetyl-CoA, two paf precursors present in high amounts in the mammalian intestine, induced paf production in three of five isolates. The platelet aggregating material extracted from H pylori exhibited biological and physiochemical characteristics identical to those of paf released from eukaryotic cells. These findings suggest that H pylori may add to the local production of paf in inflamed gastric mucosa.

Full text

PDF
1242

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste J., Le Couedic J. P., Polonsky J., Tence M. Structural analysis of purified platelet-activating factor by lipases. Nature. 1977 Sep 8;269(5624):170–171. doi: 10.1038/269170a0. [DOI] [PubMed] [Google Scholar]
  2. Benveniste J., Tencé M., Varenne P., Bidault J., Boullet C., Polonsky J. Semi-synthèse et structure proposée du facteur activant les plaquettes (P.A.F.): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Seances Acad Sci D. 1979 Nov 26;289(14):1037–1040. [PubMed] [Google Scholar]
  3. Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun. 1979 Oct 29;90(4):1194–1200. doi: 10.1016/0006-291x(79)91163-x. [DOI] [PubMed] [Google Scholar]
  4. Blaser M. J. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology. 1987 Aug;93(2):371–383. doi: 10.1016/0016-5085(87)91028-6. [DOI] [PubMed] [Google Scholar]
  5. Campylobacter-like organisms in the stomach of patients and healthy individuals. Lancet. 1984 Jun 16;1(8390):1348–1349. [PubMed] [Google Scholar]
  6. Cazenave J. P., Benveniste J., Mustard J. F. Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest. 1979 Sep;41(3):275–285. [PubMed] [Google Scholar]
  7. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  8. Denizot Y., Dassa E., Benveniste J., Thomas Y. Paf-acether production by Escherichia coli. Biochem Biophys Res Commun. 1989 Jun 15;161(2):939–943. doi: 10.1016/0006-291x(89)92689-2. [DOI] [PubMed] [Google Scholar]
  9. Denizot Y., Dassa E., Kim H. Y., Bossant M. J., Salem N., Jr, Thomas Y., Benveniste J. Synthesis of paf-acether from exogenous precursors by the prokaryote Escherichia coli. FEBS Lett. 1989 Jan 16;243(1):13–16. doi: 10.1016/0014-5793(89)81207-4. [DOI] [PubMed] [Google Scholar]
  10. Eliakim R., Karmeli F., Razin E., Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology. 1988 Nov;95(5):1167–1172. doi: 10.1016/0016-5085(88)90346-0. [DOI] [PubMed] [Google Scholar]
  11. Esplugues J. V., Whittle B. J. Gastric mucosal damage induced by local intra-arterial administration of Paf in the rat. Br J Pharmacol. 1988 Jan;93(1):222–228. doi: 10.1111/j.1476-5381.1988.tb11425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Humphreys H., Bourke S., Dooley C., McKenna D., Power B., Keane C. T., Sweeney E. C., O'Moráin C. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut. 1988 Mar;29(3):279–283. doi: 10.1136/gut.29.3.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jouvin-Marche E., Ninio E., Beaurain G., Tence M., Niaudet P., Benveniste J. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. J Immunol. 1984 Aug;133(2):892–898. [PubMed] [Google Scholar]
  14. Mencia-Huerta J. M., Roubin R., Morgat J. L., Benveniste J. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages. J Immunol. 1982 Aug;129(2):804–808. [PubMed] [Google Scholar]
  15. Morgan D. R., Freedman R., Depew C. E., Kraft W. G. Growth of Campylobacter pylori in liquid media. J Clin Microbiol. 1987 Nov;25(11):2123–2125. doi: 10.1128/jcm.25.11.2123-2125.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nunez D., Chignard M., Korth R., Le Couedic J. P., Norel X., Spinnewyn B., Braquet P., Benveniste J. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. Eur J Pharmacol. 1986 Apr 16;123(2):197–205. doi: 10.1016/0014-2999(86)90660-6. [DOI] [PubMed] [Google Scholar]
  17. Rosam A. C., Wallace J. L., Whittle B. J. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature. 1986 Jan 2;319(6048):54–56. doi: 10.1038/319054a0. [DOI] [PubMed] [Google Scholar]
  18. Slomiany B. L., Bilski J., Sarosiek J., Murty V. L., Dworkin B., VanHorn K., Zielenski J., Slomiany A. Campylobacter pyloridis degrades mucin and undermines gastric mucosal integrity. Biochem Biophys Res Commun. 1987 Apr 14;144(1):307–314. doi: 10.1016/s0006-291x(87)80511-9. [DOI] [PubMed] [Google Scholar]
  19. Sun X. M., Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest. 1988 May;81(5):1328–1331. doi: 10.1172/JCI113459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tencé V., Polonsky J., Le Couedic J. P., Benveniste M. J. Release, purification, and characterization of platelet-activating factor (PAF). Biochimie. 1980;62(4):251–259. doi: 10.1016/s0300-9084(80)80399-3. [DOI] [PubMed] [Google Scholar]
  21. Terashita Z., Imura Y., Nishikawa K., Sumida S. Is platelet activating factor (PAF) a mediator of endotoxin shock? Eur J Pharmacol. 1985 Feb 26;109(2):257–261. doi: 10.1016/0014-2999(85)90427-3. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES